Incannex Healthcare (IXHL) Competitors $2.09 -0.06 (-2.79%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends IXHL vs. ORGO, ATXS, CRVS, ALT, SANA, PROK, GLUE, PRTC, TERN, and GHRSShould you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Organogenesis (ORGO), Astria Therapeutics (ATXS), Corvus Pharmaceuticals (CRVS), Altimmune (ALT), Sana Biotechnology (SANA), ProKidney (PROK), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Terns Pharmaceuticals (TERN), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Incannex Healthcare vs. Organogenesis Astria Therapeutics Corvus Pharmaceuticals Altimmune Sana Biotechnology ProKidney Monte Rosa Therapeutics PureTech Health Terns Pharmaceuticals GH Research Incannex Healthcare (NASDAQ:IXHL) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Do analysts rate IXHL or ORGO? Organogenesis has a consensus price target of $5.33, suggesting a potential upside of 34.34%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Incannex Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Organogenesis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IXHL or ORGO? In the previous week, Organogenesis had 7 more articles in the media than Incannex Healthcare. MarketBeat recorded 11 mentions for Organogenesis and 4 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 0.75 beat Organogenesis' score of 0.70 indicating that Incannex Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, IXHL or ORGO? Incannex Healthcare has a beta of 8.11, suggesting that its share price is 711% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Which has higher earnings and valuation, IXHL or ORGO? Organogenesis has higher revenue and earnings than Incannex Healthcare. Organogenesis is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIncannex Healthcare$10K13,267.32-$18.46M-$1.39-1.50Organogenesis$433.14M1.22$4.95M-$0.06-66.17 Is IXHL or ORGO more profitable? Incannex Healthcare has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Incannex Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Incannex HealthcareN/A -182.23% -127.38% Organogenesis -1.62%-2.69%-1.63% Do insiders & institutionals believe in IXHL or ORGO? 0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 26.5% of Incannex Healthcare shares are owned by company insiders. Comparatively, 36.9% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer IXHL or ORGO? Organogenesis received 97 more outperform votes than Incannex Healthcare when rated by MarketBeat users. CompanyUnderperformOutperformIncannex HealthcareN/AN/AOrganogenesisOutperform Votes9766.44% Underperform Votes4933.56% SummaryOrganogenesis beats Incannex Healthcare on 12 of the 17 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Incannex Healthcare News Delivered to You Automatically Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IXHL vs. The Competition Export to ExcelMetricIncannex HealthcarePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$136.48M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-1.504.8389.0213.30Price / Sales13,267.32372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book20.907.876.085.74Net Income-$18.46M$153.61M$119.07M$225.93M7 Day Performance-10.68%-2.00%-1.84%-1.32%1 Month Performance-7.52%-7.47%-3.65%0.60%1 Year Performance144.27%31.80%31.62%26.23% Incannex Healthcare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IXHLIncannex Healthcare1.3552 of 5 stars$2.09-2.8%N/A+132.2%$136.48M$10,000.00-1.503Gap UpORGOOrganogenesis4.0957 of 5 stars$3.97-2.7%$5.33+34.3%+51.5%$540.91M$433.14M0.00950Analyst RevisionATXSAstria Therapeutics1.7093 of 5 stars$9.58-1.7%$25.60+167.2%+110.5%$540.60MN/A-4.5830Analyst RevisionCRVSCorvus Pharmaceuticals2.8214 of 5 stars$8.24-1.9%$12.83+55.7%+449.3%$539.76MN/A0.0030Analyst RevisionALTAltimmune1.9231 of 5 stars$8.05+7.8%$20.00+148.4%+206.1%$531.30M$430,000.000.0050Analyst RevisionSANASana Biotechnology2.2165 of 5 stars$2.53+7.2%$13.50+433.6%-41.2%$526.91MN/A0.00328PROKProKidney2.5885 of 5 stars$1.65-8.3%$4.50+172.7%-6.3%$521.41MN/A0.003GLUEMonte Rosa Therapeutics2.9578 of 5 stars$8.36+0.6%$16.00+91.4%+157.2%$510.54MN/A0.0090PRTCPureTech Health2.2347 of 5 stars$21.70+2.1%$45.00+107.4%+0.9%$508.96M$3.33M0.00100News CoveragePositive NewsTERNTerns Pharmaceuticals4.327 of 5 stars$5.60-5.2%$27.25+386.6%+49.3%$501.99M$1M0.0040GHRSGH Research1.3894 of 5 stars$10.95+13.9%$35.67+225.7%+77.2%$499.99MN/A0.0010Analyst Forecast Related Companies and Tools Related Companies Organogenesis Alternatives Astria Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Altimmune Alternatives Sana Biotechnology Alternatives ProKidney Alternatives Monte Rosa Therapeutics Alternatives PureTech Health Alternatives Terns Pharmaceuticals Alternatives GH Research Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IXHL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incannex Healthcare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incannex Healthcare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
